Voluntis : Transition vers un modèle de revenus récurrents
>Résultats S1 2018 - Voluntis a publié jeudi dernier ses chiffres au titre du S1 2018, le CA ressort à 2.2 M€ sur la période contre 5.7 M€ au S1 2017. Un recul qui reflète la transition du revenu du groupe de produits de pré-lancements (upfront, milestones et co-développement) vers un CA récurrent issu de l’activité de commercialisation de ses solutions (0.1 M€ de milestones au S1 2018 vs 3.5 M€ su S1 2017). La perte opérationnelle se creuse en conséquence à 7.9 M€ (...Voluntis SA is a France-based company specialized in medical solutions. The Company designs prescription applications that embed medical intelligence in the smart phones of people suffering from chronic and rare diseases. Voluntis SA develops digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Its product portfolio includes Insulia, a prescription-only medical device, which is a digital therapeutic for people with type 2 diabetes who are being treated with long-acting basal insulin. The medical device also provides patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; Theraxium platform, which is a flexible platform that transforms health data into medical intelligence, and Quality and Regulatory Expertise, which focuses on patient safety, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.